An observational study in Physical Performance Decline in Older Adults, Sarcopenia and Muscle Fat Infiltration, sponsored by Nantes University Hospital. Recruiting at 1 site in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Nantes University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Sarcopenia with a site in France — 23 open to participants now, 24 under way, none of them phase 3. Sarcopenia · France.
Among the 78 studies in Sarcopenia with a site in France, this one is the 9th largest by planned enrollment of the 25 observational ones that give a count, is one of 6 that started in 2026, is one of 25 observational ones, reaches primary completion later than 18 of the 23 other live ones, and was the 74th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →23 of the 78 studies in Sarcopenia with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 65+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 75+
Hospices Civils de Lyon · Sites in France
Ages 18–74
Hospices Civils de Lyon · Sites in France
Ages 18–74
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 75 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2026.
This study's planned enrollment of 115 is close to the median of 120 across 455 observational studies indexed under Sarcopenia.
Median enrollment 98 across the 53 interventional studies, 72 across the 25 observational. Of the 38 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 78 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 3 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
9 of the studies in Sarcopenia with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05228262University Hospital, Clermont-FerrandVascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis | 2027-02-01 |
| NCT05488093University Hospital, MontpellierEvaluation of Mobility in Subjects With Severe Knee Osteoarthritis Who Are to Undergo Total Knee Replacement | 2027-03 |
| NCT06963359Assistance Publique - Hôpitaux de ParisHigh-definition Surface Electromyography Markers for the Diagnosis and Monitoring of Sarcopenia | 2027-03 |
| NCT05869487Centre Hospitalier Régional d'OrléansCalf Circumference Versus X-ray Absorptiometry in the Diagnosis of Sarcopenia in Elderly Hospitalized Patients | 2027-04-11 |
| NCT07864857University Hospital, GrenobleAutomated and Reliable Estimation of Patient Height From CT Scan Using an Artificial Intelligence Algorithm | 2027-04-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 78 studies in Sarcopenia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sarcopenia in older adults is associated not only with loss of muscle mass but also with deterioration of muscle quality, particularly intramuscular fat infiltration. While muscle mass is commonly assessed, muscle quality remains insufficiently explored in routine clinical practice.
The FATUS-OLD study aims to evaluate the clinical relevance of a novel ultrasound-based multiparametric approach to assess intramuscular fat infiltration and muscle volume in hospitalized older adults undergoing rehabilitation. The main hypothesis is that higher intramuscular fat infiltration at baseline is associated with poorer recovery of physical performance at 6 months, independently of muscle volume.
This non-invasive, rapid, and radiation-free imaging approach could improve sarcopenia phenotyping and help identify new prognostic biomarkers for clinical follow-up and future interventional trials.
FATUS-OLD is a prospective, monocentric, open-label, non-randomized observational study conducted at Nantes University Hospital. The study includes older adults aged 75 years and older hospitalized in a rehabilitation day-hospital program for gait or balance disorders.
Participants undergo ultrasound assessments of skeletal muscle using a CE-marked ultrasound device capable of measuring muscle volume and intramuscular fat infiltration through matrix-based analysis. Measurements are performed at baseline and during follow-up.
The primary objective is to assess the prognostic value of baseline intramuscular fat infiltration on physical performance recovery at 6 months, evaluated using the Short Physical Performance Battery (SPPB). Secondary objectives include the relationship between muscle volume, muscle quality, muscle strength, appendicular lean mass measured by bioelectrical impedance analysis, and clinically significant events such as falls, loss of independence, rehospitalization, and mortality.
The study is exploratory and aims to validate innovative ultrasound-derived biomarkers of muscle quality in a real-life geriatric population.
All participants undergo standardized clinical assessments and ultrasound-based muscle evaluations as part of routine rehabilitation follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants undergo standardized clinical assessments and ultrasound-based muscle evaluations as part of routine rehabilitation follow-up.
Change in Short Physical Performance Battery (SPPB) score
Difference between SPPB score at baseline and at 6 months, used to evaluate recovery of physical performance in relation to baseline intramuscular fat infiltration.
Time frame: Baseline to 6 months
Association between muscle volume and appendicular lean mass
Correlation between ultrasound-derived muscle volume (with and without correction for intramuscular fat infiltration) and appendicular lean mass measured by bioelectrical impedance analysis.
Time frame: Baseline
Association between muscle volume and muscle strength
Relationship between muscle volume and maximal muscle strength for corresponding muscle groups, with and without correction for intramuscular fat infiltration.
Time frame: Baseline and 6 months
Occurrence of clinically significant events
Incidence of falls, loss of independence, rehospitalization, cognitive decline, institutionalization, and mortality.
Time frame: Up to 6 months
Started May 2026 (actual). Primary completion is estimated for Nov 2028, 30 months after the start.
Of 192 non-industry observational studies under Sarcopenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 30 months is above that.
Counting every sponsor, half of 194 studies reached it within 26 months; a quarter within 12 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.